secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001193125-25-015648
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Phase 2 risvodetinib trial misses primary efficacy endpoint; development paused
--------------------------------------------------------------------------------

- Trial enrolled 126 untreated Parkinson's patients; 95% completed 12 weeks with safety comparable to placebo.
- No improvement on primary efficacy measure MDS-UPDRS Parts 2+3 at any dose vs placebo.
- Secondary signals: Part 2 improved -1.41 at 100 mg (p=0.036); Schwab & England +4% at 50 mg (p=0.0004).
- Skin biopsy analysis suggests treatment-dependent reduction in neuronal alpha-synuclein deposition.
- Company pausing risvodetinib to focus resources on IkT-001Pro for PAH; evaluating strategic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525015648/0001193125-25-015648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525015648/d919757d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-015648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer